tetano
Editor, Senior Moderator
Open Forum Infect Dis
. 2022 Apr 14;9(7)
fac204.
doi: 10.1093/ofid/ofac204. eCollection 2022 Jul.
Outcomes of B-Cell-Depleted Patients With Coronavirus Disease 2019 Treated With Antispike Monoclonal Antibodies
Zachary A Yetmar[SUP] 1 [/SUP], Ryan B Khodadadi[SUP] 1 [/SUP], Maria Teresa Seville[SUP] 2 [/SUP], Lisa Brumble[SUP] 3 [/SUP], John C O'Horo[SUP] 1 [/SUP], Ravindra Ganesh[SUP] 4 [/SUP], Raymund R Razonable[SUP] 1 [/SUP]
Affiliations
Abstract
Antispike monoclonal antibody treatment of 180 B-cell-depleted patients with mild-to-moderate coronavirus disease 2019 (COVID-19) resulted in good outcomes overall, with only 12.2% progressing to severe disease, 9.4% requiring hospitalization, 0.6% requiring mechanical ventilation, no deaths within 30 days, and 1.8% developing persistent COVID-19. Antispike monoclonal antibodies appear effective in this immunocompromised population.
Keywords: COVID-19; SARS-CoV-2; anti-CD20; monoclonal antibody; rituximab.
. 2022 Apr 14;9(7)
fac204.doi: 10.1093/ofid/ofac204. eCollection 2022 Jul.
Outcomes of B-Cell-Depleted Patients With Coronavirus Disease 2019 Treated With Antispike Monoclonal Antibodies
Zachary A Yetmar[SUP] 1 [/SUP], Ryan B Khodadadi[SUP] 1 [/SUP], Maria Teresa Seville[SUP] 2 [/SUP], Lisa Brumble[SUP] 3 [/SUP], John C O'Horo[SUP] 1 [/SUP], Ravindra Ganesh[SUP] 4 [/SUP], Raymund R Razonable[SUP] 1 [/SUP]
Affiliations
- PMID: 35791358
- PMCID: PMC9047222
- DOI: 10.1093/ofid/ofac204
Abstract
Antispike monoclonal antibody treatment of 180 B-cell-depleted patients with mild-to-moderate coronavirus disease 2019 (COVID-19) resulted in good outcomes overall, with only 12.2% progressing to severe disease, 9.4% requiring hospitalization, 0.6% requiring mechanical ventilation, no deaths within 30 days, and 1.8% developing persistent COVID-19. Antispike monoclonal antibodies appear effective in this immunocompromised population.
Keywords: COVID-19; SARS-CoV-2; anti-CD20; monoclonal antibody; rituximab.